NCT02550106 - Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment | Biotech Hunter

Enrollment

136

Participants

Timeline

Start Date

April 22, 2015

Primary Completion Date

January 11, 2016

Study Completion Date

January 11, 2016

Conditions

CHRONIC SPONTANEOUS URTICARIA

Interventions

DRUG

OMALIZUMAB

sub cutaneous injections of 300 mg every 4 weeks until Week 8.

Trial Locations (29)

13885

Novartis Investigative Site, Marseille

21034

Novartis Investigative Site, Dijon

25030

Novartis Investigative Site, Besançon

29000

Novartis Investigative Site, Quimper

30029

Novartis Investigative Site, Nîmes

31400

Novartis Investigative Site, Toulouse

33075

Novartis Investigative Site, Bordeaux

34295

Novartis Investigative Site, Montpellier

35033

Novartis Investigative Site, Rennes

38043

Novartis Investigative Site, Grenoble

42055

Novartis Investigative Site, Saint-Etienne

44035

Novartis Investigative Site, Nantes

49933

Novartis Investigative Site, Angers

51005

Novartis Investigative Site, Châlons-en-Champagne

51090

Novartis Investigative Site, Reims

54511

Novartis Investigative Site, Vandœuvre-lès-Nancy

59000

Novartis Investigative Site, Lille

59037

Novartis Investigative Site, Lille

63003

Novartis Investigative Site, Clermont-Ferrand

69317

Novartis Investigative Site, Lyon

75014

Novartis Investigative Site, Paris

75475

Novartis Investigative Site, Paris

75877

Novartis Investigative Site, Paris

76031

Novartis Investigative Site, Rouen

83800

Novartis Investigative Site, Toulon

87000

Novartis Investigative Site, Limoges

93009

Novartis Investigative Site, Bobigny

95107

Novartis Investigative Site, Argenteuil

06202

Novartis Investigative Site, Nice